Clinical perspective on regional nodal irradiation for breast cancer
TL;DR10-yr DFS 82% vs 77% (MA.20) and 72.1% vs 69.1% (EORTC 22922) with RNI, no OS gain in either trial alone.
NCIC MA.20EORTC 22922AMAROSACOSOG Z0011Alliance A011202NSABP-B51
The transferable detail is target volume: MA.20 treated IMC, SCV and level III axilla after BCS in a cohort roughly 85% 1-3 node-positive, while EORTC 22922 treated IMC plus medial SCV with 44.4% node-negative in the RNI arm. Both DFS gains (82% vs 77%; 72.1% vs 69.1%) support nodal fields in higher-risk pN1, with IMC coverage planned against cardiac dose.
Target volume is what transfers: MA.20 treated IMC, SCV and level III axilla after BCS, EORTC 22922 treated IMC plus medial SCV. DFS gains in both support nodal fields in higher-risk pN1, and the CAD 18% vs 7% IMC series argues for heart-sparing IMC planning, not omission.
Extent of axillary surgery now feeds the RNI decision. AMAROS put axillary RT against ALND (5-yr axillary recurrence 1.19% vs 0.43%, less lymphedema), and Z0011's SLN-alone arm had LRR 1.6% with many receiving high tangents, so surgical choice and nodal field design are coupled.
9 details 5 trials watching
Target volumes differ by trial: MA.20 treated the undissected axilla, IMC (first 3 intercostal spaces) and SCV; EORTC 22922 treated IMC and medial SCV. Z0011-era high tangents cover most of level I/II but not level III or SCV.
RNI adds cardiopulmonary toxicity and lymphedema risk, worst after complete ALND. Coronary events rose 7.4% per Gy mean heart dose in a 1958-2001 series, and a retrospective series showed CAD 18% vs 7% with vs without IMC fields (P=0.01).
EBCTCG PMRT data in 1-3 node disease frame the debate; MA.20 and EORTC 22922 test it with CT-era RT. AMAROS and ACOSOG Z0011 recast the axilla as an RT target after limited SLN disease.
Narrative, not systematic; cardiac evidence mixes pre-CT-era and retrospective series. Trial-era pN1 differs from today's microsectioned, SLN-staged pN1, so absolute gains may not transfer.
Authors favor RNI for advanced and high-risk stage II disease and ask that grade, subtype, nodal burden and extent of axillary surgery guide stage I-II decisions. Recurrence-score-guided RNI is proposed but untested prospectively.
| Characteristic | NCIC MA.20 | EORTC 22922 |
|---|---|---|
| Accrual | 2000-2007 | 1996-2004 |
| N | 1832 | 4004 |
| BCS | 100% | 76.1% |
| RNI targets | IMC + SCV + level III axilla | IMC + medial SCV |
| Median age (yr) | 53-54 | 54 |
| 0 ALN+ (RNI vs control) | 9.6% vs 9.7% | 44.4% vs 44.5% |
| 1-3 ALN+ (RNI vs control) | 84.9% vs 85.1% | 42.9% vs 43.3% |
| >3 ALN+ (RNI vs control) | 5.5% vs 5.1% | 12.2% vs 12.2% |
| Chemotherapy (RNI vs control) | 90.7% vs 90.5% | 54.6% vs 55.1% |
| Endpoint | NCIC MA.20 | EORTC 22922 |
|---|---|---|
| 10-yr DFS | 82% vs 77%, P=0.01 | 72.1% vs 69.1%, P=0.04 |
| 10-yr distant DFS | Not stated in source text | 78% vs 75.5%, P=0.02 |
| 10-yr BC mortality | Not stated in source text | 12.5% vs 14.4%, P=0.02 |
| 10-yr OS | No long-term benefit | No long-term benefit |
- Does RNI benefit favorable stage II or luminal pN1 disease? recruiting The T-REX Trial: Tailored Regional External Beam Radiotherapy in Clinically Node-negative Breast Cancer Patients With 1-2 Sentinel Node Macrometastases. Phase NAn=1350 · primary completion 2028-12 · RCT omitting regional RT in ER+/HER2- 1-2 SN macrometsrecruiting Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer Phase 3n=3142 · primary completion 2029-11 · phase 3 RNI in pT1-2N1 intermediate-risk disease
- Is RNI needed after nodal pCR following neoadjuvant chemotherapy? active Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Phase NAn=1636 · primary completion 2023-09 · randomized phase 3 regional nodal XRT after chemo + surgeryn=100 · primary completion 2028-06 · RNI de-escalation in cN1→ypN0 after neoadjuvant therapyrecruiting Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy Phase NAn=1900 · primary completion 2030-02 · omits axillary RT if SNB node-negative after NACT; DFS
- Can recurrence score select pts for RNI?
📚 Sources · 📄 1 paper
The longer read
The review's core claim is that RNI in pN1 disease rests on two trials that answered slightly different questions, and that their modest absolute gains have to be re-weighed against a population that has changed since they accrued. MA.20 was almost entirely a 1-3 node, breast-conservation, chemotherapy-treated cohort with level III axilla in the field. EORTC 22922 mixed mastectomy and BCS, enrolled a large node-negative fraction on the basis of tumor location, and treated a narrower IMC plus medial SCV volume. That both showed DFS and distant DFS gains without an individual OS gain is the consistent finding. The pooled analysis with the French IMC trial is what supplies the absolute 1-2% OS figure, and that figure carries the review's argument that RNI is not merely a locoregional intervention.
The weaker part of the argument is transfer. The authors identify two forces eroding the trial-era baseline: SLN microsectioning and immunohistochemistry, which convert 10 to 50% of negative nodes to positive and so dilute today's pN1 with low-burden disease, and the move from ALND to SLN biopsy alone, which changes what is left undissected and therefore what RNI is treating. A reader should expect the absolute benefit in a modern, micrometastasis-enriched pN1 population to be smaller than the trial numbers, not equal to them, although the review cannot say by how much.
Z0011 sits awkwardly in this frame, and the review is candid about it. The SLN-alone arm's low regional recurrence is often cited as evidence the axilla can be left alone, yet among those with detailed RT records roughly half received high tangents and 19% received dedicated nodal fields. That makes Z0011 partly an unplanned nodal RT trial, and it limits how far it can support omission of nodal RT. AMAROS is the cleaner comparison, axillary RT against completion dissection, with less lymphedema and low axillary recurrence in both arms, though it was not powered for non-inferiority.
On toxicity, the cardiac data cited combine a pre-CT-era dose-response series with a retrospective IMC-field series, so they argue for heart-sparing IMC planning rather than for dropping the IMC. The proposed selectors (nodal ratio, age, grade, LVI, ECE, subtype, recurrence score) are reasonable but none has been tested as an RNI selector. The Danish PMRT tissue analysis, in which the OS benefit was confined to ER/PR-positive, HER2-negative disease, cuts against using a luminal subtype to de-escalate nodal RT.
The review dates from 2017. Its post-neoadjuvant guidance points to NSABP-B51 and Alliance A011202 as the trials that would settle RNI after nodal response and after SLN positivity following NAC. Both were open when it was written, so that section frames the question rather than answering it, and should be read against those trials' own reports.